A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Hirsutism is excessive body hair on parts of the body where hair is normally absent or minimal. The word is from the early 17th century: from Latin hirsutus meaning "hairy". It usually refers to a male pattern of hair growth in a female that may be a sign of a more serious medical condition, especially if it develops well after puberty. Cultural stigma against hirsutism can cause much psychological distress and social difficulty. Discrimination based on facial hirsutism often leads to the avoidance of social situations and to symptoms of anxiety and depression. Hirsutism is usually the result of an underlying endocrine imbalance, which may be adrenal, ovarian, or central. It can be caused by increased levels of androgen hormones. The amount and location of the hair is measured by a Ferriman–Gallwey score. It is different from hypertrichosis, which is excessive hair growth anywhere on the body. Treatments may include certain birth control pills, antiandrogens, or insulin sensitizers. Hirsutism affects between 5 and 15% of women across all ethnic backgrounds. Depending on the definition and the underlying data, approximately 40% of women have some degree of facial hair. About 10 to 15% of cases of hirsutism are idiopathic with no known cause.
=== EC 1.14.12 With NADH or NADPH as one donor, and incorporation of two atoms of oxygen into one donor === EC 1.14.12.1: anthranilate 1,2-dioxygenase (deaminating, decarboxylating) EC 1.14.12.2: Now EC 1.14.13.35 anthranilate 3-monooxygenase (deaminating) EC 1.14.12.3: benzene 1,2-dioxygenase EC 1.14.12.4: EC 1.14.13.242, 3-hydroxy-2-methylpyridinecarboxylate monooxygenase EC 1.14.12.5: Now EC .14.13.241, 5-pyridoxate monooxygenase EC 1.14.12.6: Now EC 1.14.13.66, 2-hydroxycyclohexanone 2-monooxygenase EC 1.14.12.7: phthalate 4,5-dioxygenase EC 1.14.12.8: 4-sulfobenzoate 3,4-dioxygenase EC 1.14.12.9: 4-chlorophenylacetate 3,4-dioxygenase EC 1.14.12.10: benzoate 1,2-dioxygenase EC 1.14.12.11: toluene dioxygenase EC 1.14.12.12: naphthalene 1,2-dioxygenase EC 1.14.12.13: 2-halobenzoate 1,2-dioxygenase EC 1.14.12.14: 2-aminobenzenesulfonate 2,3-dioxygenase EC 1.14.12.15: terephthalate 1,2-dioxygenase EC 1.14.12.16: 2-hydroxyquinoline 5,6-dioxygenase EC 1.14.12.17: nitric oxide dioxygenase EC 1.14.12.18: biphenyl 2,3-dioxygenase EC 1.14.12.19: 3-phenylpropionate dioxygenase EC 1.14.12.20: Now classified as EC 1.14.15.17, pheophorbide a oxygenase. EC 1.14.12.21: Now EC 1.14.13.208, benzoyl-CoA 2,3-epoxidase EC 1.14.12.22: carbazole 1,9a-dioxygenase EC 1.14.12.23: nitroarene dioxygenase EC 1.14.12.24: 2,4-dinitrotoluene dioxygenase EC 1.14.12.25: p-cumate 2,3-dioxygenase EC 1.14.12.26: chlorobenzene dioxygenase
=== Apical delta === Apical delta refers to the branching pattern of small accessory canals and minor foramina seen at the tip or apex of some tooth roots. The pattern is said to be reminiscent of a river delta when sectioned and viewed using a microscope. Because the anatomy of this area is very small and complex with several portals of entry to the root canal i.e. more than one apical foramen.
Sources: en.wikipedia.org
Cysteine dioxygenase (CDO), and sulfinoalanine decarboxylase can turn cysteine into hypotaurine and then taurine. Alternately, the cysteine from the cystathionine gamma-lyase can be used by the enzymes glutamate–cysteine ligase (GCL) and glutathione synthetase (GSS) to produce glutathione.
During the trial of alleged 9/11 conspirator Zacarias Moussaoui, the U.S. government identified five people as having been completely aware of the operation's details; bin Laden, Mohammed, Mohammed Atef, Abu Turab al-Urduni, and bin al-Shibh. The attacks were conceived by Khalid Sheikh Mohammed, who first presented it to bin Laden in 1996. Many targets were listed that al-Qaeda hijackers could crash planes into, including the Library Tower (now the U.S. Bank Tower) in Los Angeles. Bin Laden rejected the plan for being too elaborate. Al-Qaeda's first attacks against the U.S. after Bin Laden's 1998 fatwa were the 1998 African embassy bombings. In late 1998 or early 1999, bin Laden approved Mohammed to go forward with a new version of the 1996 plan. Bin Laden provided leadership and financial support, and was involved in selecting participants. Atef provided operational support, including target selections and helping arrange travel for the hijackers. He initially selected Nawaf al-Hazmi and Khalid al-Mihdhar, both experienced jihadists who had fought in the Bosnian war. The two arrived in the United States in mid-January 2000. In early 2000, they took flying lessons in San Diego, California. Both spoke little English. They performed poorly in flying lessons, and so they eventually served as secondary "muscle" hijackers. The Hamburg cell in Germany included Islamists who were key operatives in the 9/11 attacks. In late 1999, cell members bin al-Shibh, Mohamed Atta, Marwan al-Shehhi, and Ziad Jarrah arrived to meet al-Qaeda in Afghanistan.
== M == MALDI – Matrix-assisted laser desorption/ionization MBE – Molecular beam epitaxy MEIS – Medium energy ion scattering MFM – Magnetic force microscopy MIT – Magnetic induction tomography MPM – Multiphoton fluorescence microscopy MRFM – Magnetic resonance force microscopy MRI – Magnetic resonance imaging MS – Mass spectrometry MS/MS – Tandem mass spectrometry MSGE – Mechanically stimulated gas emission Mössbauer spectroscopy MTA – Microthermal analysis
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.